Status:
UNKNOWN
Transplantation of hAMSCs for Woman With DOR
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Diminished Ovarian Response
Eligibility:
FEMALE
35-45 years
Phase:
PHASE1
Brief Summary
Patients with Diminished ovarian response (DOR）have a poor in vitro fertilization（IVF） outcome, and is considered one of most challenging tasks in artificial reproductive treatment (ART). Stem cell th...
Detailed Description
Patients with Diminished ovarian response (DOR）have a poor in vitro fertilization（IVF） outcome, and is considered one of most challenging tasks in artificial reproductive treatment (ART). Stem cell th...
Eligibility Criteria
Inclusion
- Women between35 and 45 years, who is diagnosed with Diminished Ovarian Reserve by Bologna criteria, (AFC≤7，or serum AMH level \< 1.10ng/ml), and failed pregnancies in at least two cycles of In Vitro Fertilization(IVF) or Intracytoplasmic Sperm Injection(ICSI).
- Willing to sign the Informed Consent Form.
Exclusion
- Patients diagnosed with hereditary, immunological and iatrogenic premature ovarian failure
- Patients allergy to blood products
- Patients diagnosed with abnormal coagulation function
- Patients diagnosed with uterine malformation
- Patients undergoing Preimplantation Genetic Testing
- Patients diagnosed with hydrosalpinx
- Patients diagnosed with infectious diseases
- Contraindications for In Vitro Fertilization-Embryo Transfer(IVF-ET) or pregnancy
- Prior personal history of stem cell clinical trail or other clinical trails
- Unwilling to comply with study protocol
- Patients identified with high risk for stem cell injection
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04706312
Start Date
April 1 2021
End Date
April 1 2024
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Center of Reproductive Medicine at the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000